- Home
- ONTO vs NUVL Comparison
ONTO vs NUVL Comparison
Compare ONTO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTO
- NUVL
- Stock Information
- Founded
- ONTO 1940
- NUVL 2017
- Country
- ONTO United States
- NUVL United States
- Employees
- ONTO N/A
- NUVL N/A
- Industry
- ONTO Industrial Machinery/Components
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ONTO Industrials
- NUVL Health Care
- Exchange
- ONTO Nasdaq
- NUVL Nasdaq
- Market Cap
- ONTO 6.1B
- NUVL 5.6B
- IPO Year
- ONTO N/A
- NUVL 2021
- Fundamental
- Price
- ONTO $90.53
- NUVL $71.76
- Analyst Decision
- ONTO Strong Buy
- NUVL Strong Buy
- Analyst Count
- ONTO 9
- NUVL 8
- Target Price
- ONTO $203.75
- NUVL $115.50
- AVG Volume (30 Days)
- ONTO 931.4K
- NUVL 660.5K
- Earning Date
- ONTO 05-08-2025
- NUVL 05-08-2025
- Dividend Yield
- ONTO N/A
- NUVL N/A
- EPS Growth
- ONTO 65.04
- NUVL N/A
- EPS
- ONTO 4.06
- NUVL N/A
- Revenue
- ONTO $987,321,000.00
- NUVL N/A
- Revenue This Year
- ONTO $13.24
- NUVL N/A
- Revenue Next Year
- ONTO $9.12
- NUVL N/A
- P/E Ratio
- ONTO $31.23
- NUVL N/A
- Revenue Growth
- ONTO 21.02
- NUVL N/A
- 52 Week Low
- ONTO $98.21
- NUVL $55.54
- 52 Week High
- ONTO $238.93
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ONTO 30.62
- NUVL 51.04
- Support Level
- ONTO $120.62
- NUVL $63.56
- Resistance Level
- ONTO $129.77
- NUVL $78.97
- Average True Range (ATR)
- ONTO 4.95
- NUVL 3.30
- MACD
- ONTO -0.70
- NUVL -0.20
- Stochastic Oscillator
- ONTO 2.65
- NUVL 59.65
About ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.